Cargando…

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug

Detalles Bibliográficos
Autor principal:	Stewart, Michael W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432488/ https://www.ncbi.nlm.nih.gov/pubmed/22446028 http://dx.doi.org/10.1136/bjophthalmol-2011-300654

Ejemplares similares

Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept
por: Hong, Hye Kyoung, et al.
Publicado: (2020)

Gene expression profile of the murine ischemic retina and its response to Aflibercept (VEGF-Trap)
por: Rojo Arias, Jesús Eduardo, et al.
Publicado: (2021)

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
por: Ichiyama, Yusuke, et al.
Publicado: (2022)

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
por: Malik, Deepika, et al.
Publicado: (2014)

Anti-VEGF and Beyond
por: Bertelmann, T., et al.
Publicado: (2017)

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
por: Stewart, Michael W
Publicado: (2012)

The use of aflibercept (VEGF trap) in mitigating sulfur mustard-induced corneal neovascularization in a rabbit model
por: Gore, Ariel, et al.
Publicado: (2023)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
por: Schargus, Marc, et al.
Publicado: (2021)

Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)

Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
por: Mira, Filipe, et al.
Publicado: (2017)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

Pharmacokinetics of Anti‐VEGF Agent Aflibercept in Cancer Predicted by Data‐Driven, Molecular‐Detailed Model
por: Finley, SD, et al.
Publicado: (2015)

Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept
por: Du, Liping, et al.
Publicado: (2015)

Microporous Drug Delivery System for Sustained Anti-VEGF Delivery to the Eye
por: Zhou, Chengxin, et al.
Publicado: (2020)

Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice
por: Kim, Il-doo, et al.
Publicado: (2021)

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
por: Wang-Gillam, Andrea, et al.
Publicado: (2011)

The Newest of Our Creeds
Publicado: (1878)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose
por: Veritti, Daniele, et al.
Publicado: (2023)

Anti-VEGF drugs in the prevention of blindness
por: Yorston, David
Publicado: (2014)

Anti-VEGF drugs: evidence for effectiveness
por: Evans, Jennifer, et al.
Publicado: (2014)

Compartment Model Predicts VEGF Secretion and Investigates the Effects of VEGF Trap in Tumor-Bearing Mice
por: Finley, Stacey D., et al.
Publicado: (2013)

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
por: Papadopoulos, Nicholas, et al.
Publicado: (2012)

Aflibercept Nanoformulation Inhibits VEGF Expression in Ocular In Vitro Model: A Preliminary Report
por: Kelly, Shannon J., et al.
Publicado: (2018)

Issues with Intravitreal Administration of Anti-VEGF Drugs
por: Schargus, Marc, et al.
Publicado: (2020)

Expounding newer vistas in VEGF
por: Natarajan, Sundaram
Publicado: (2013)

Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
por: Kucukevcilioglu, Murat, et al.
Publicado: (2023)

Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
por: Miyamoto, Noriko, et al.
Publicado: (2017)

Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases
por: Sharma, Dhyana, et al.
Publicado: (2023)

Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
por: Zhang, Zhao, et al.
Publicado: (2022)

Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedside
por: Al-Halafi, Ali M.
Publicado: (2014)

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
por: Ria, Roberto, et al.
Publicado: (2020)

Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice
por: Veritti, Daniele, et al.
Publicado: (2022)

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
por: Sheth, Jay U, et al.
Publicado: (2021)

A Compartment Model of VEGF Distribution in Humans in the Presence of Soluble VEGF Receptor-1 Acting as a Ligand Trap
por: Wu, Florence T. H., et al.
Publicado: (2009)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
por: Lieu, Christopher H., et al.
Publicado: (2013)

Use of intravitreal anti-VEGF: Retinopathy of prematurity surgeons’ in Hamlet's dilemma?
por: Azad, Rajvardhan
Publicado: (2011)

Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
por: Yamashita, Mariko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tkfcqqcojek2t330p3e1t0jnkl